Clal Bio: A subsidiary in negotiations for the development of a vaccine for Corona – the capital market

Elicio’s vaccine consists of a portion of the viral protein necessary for the virus to enter the cells, combined with an immune response stimulant developed by the company. In her estimation, the technology developed by her will stimulate the components of the immune system in the lymph nodes, and will induce high levels of antibody response (including neutralizing antibodies) and cellular immune response (T-cell response).

The company also estimates that its vaccine, if developed, will not require special means of transport and freezing for the purpose of distributing the vaccine.

Elicio is an American private company operating in the field of immunotherapy, and is developing Amphiphile Vaccines vaccine technology that originates from the Massachusetts Institute of Technology (MIT). This technology enables the presentation of targets of cancer cells and pathogens to the immune system in a way that is expected to elicit a particularly effective and long-lasting immune response. Amphiphile Vaccines technology also has the potential to assist in CAR-T treatments (including against solid tumors), and in the safe and effective administration of adjuvants. Elicio plans to launch in the coming months a Phase I / II clinical trial of the KRAS mutation in gastrointestinal cancers carrying this mutation, as well as a clinical trial of the COVID-19 vaccine.

Dividend of NIS 36 million – after self-purchases
Earlier this week, we reported that following the sale of Cadet (Cadent Therapeutics Inc), the company’s board of directors decided to distribute a dividend of NIS 36 million, subject to court approval.

It should be noted that the dividend distribution comes after only two weeks ago the company decided to make self-purchases in the amount of up to NIS 10 million.

In addition, the FDA approved a subsidiary of Clal Biotechnology to continue the anticoagulant trial that inhibits the development of blood clots in corona patients in critical condition who are hospitalized in intensive care units. This is phase 2 and they will test the safety of the high dose of the drug on 30 patients. The stock soared last night in trading, when it has already risen by 50% since the beginning of the year and by 65% ​​in the last 12 months. Following the enjoyable rally, Clal is now trading at its highest value since July 2019. (For the full article).